- Home
- NEWT vs CCCC Comparison
NEWT vs CCCC Comparison
Compare NEWT & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWT
- CCCC
- Stock Information
- Founded
- NEWT 1998
- CCCC 2015
- Country
- NEWT United States
- CCCC United States
- Employees
- NEWT N/A
- CCCC N/A
- Industry
- NEWT Major Banks
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- NEWT Finance
- CCCC Health Care
- Exchange
- NEWT Nasdaq
- CCCC Nasdaq
- Market Cap
- NEWT 281.1M
- CCCC 104.4M
- IPO Year
- NEWT N/A
- CCCC 2020
- Fundamental
- Price
- NEWT $11.66
- CCCC $2.26
- Analyst Decision
- NEWT Hold
- CCCC Buy
- Analyst Count
- NEWT 4
- CCCC 3
- Target Price
- NEWT $13.75
- CCCC $12.00
- AVG Volume (30 Days)
- NEWT 194.0K
- CCCC 1.6M
- Earning Date
- NEWT 07-28-2025
- CCCC 07-31-2025
- Dividend Yield
- NEWT 6.55%
- CCCC N/A
- EPS Growth
- NEWT 27.62
- CCCC N/A
- EPS
- NEWT 1.92
- CCCC N/A
- Revenue
- NEWT $352,584,000.00
- CCCC $39,783,000.00
- Revenue This Year
- NEWT N/A
- CCCC N/A
- Revenue Next Year
- NEWT $13.51
- CCCC N/A
- P/E Ratio
- NEWT $6.03
- CCCC N/A
- Revenue Growth
- NEWT 23.06
- CCCC 98.56
- 52 Week Low
- NEWT $9.12
- CCCC $1.09
- 52 Week High
- NEWT $15.49
- CCCC $7.66
- Technical
- Relative Strength Index (RSI)
- NEWT 63.17
- CCCC 63.62
- Support Level
- NEWT $11.60
- CCCC $1.36
- Resistance Level
- NEWT $11.00
- CCCC $2.17
- Average True Range (ATR)
- NEWT 0.31
- CCCC 0.15
- MACD
- NEWT 0.10
- CCCC 0.05
- Stochastic Oscillator
- NEWT 86.39
- CCCC 67.11
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.